What is Armata Pharmaceuticals?
Armata Pharmaceuticals is a clinical-stage biotechnology enterprise dedicated to the development of precisely targeted bacteriophage therapeutics. Founded in 2005 and headquartered in Marina del Rey, California, the company focuses on combating multidrug-resistant bacterial infections, a significant challenge in modern healthcare. By utilizing bacteriophages—viruses that specifically target and eliminate bacteria—Armata is pioneering a novel therapeutic modality that offers a high degree of specificity compared to traditional broad-spectrum antibiotics. This market position is bolstered by a robust intellectual property portfolio and a commitment to addressing unmet medical needs in infectious disease management.
How much funding has Armata Pharmaceuticals raised?
Armata Pharmaceuticals has raised a total of $143.8M across 5 funding rounds:
Series A
$13.3M
Series D
$60.5M
Unspecified
$5M
Share Placement
$20M
Share Placement
$45M
Series A (2013): $13.3M, investors not publicly disclosed
Series D (2014): $60.5M led by Renaissance Holding Company
Unspecified (2014): $5M supported by Delta Dental of New Jersey
Share Placement (2021): $20M, investors not publicly disclosed
Share Placement (2022): $45M backed by Innoviva
Key Investors in Armata Pharmaceuticals
Innoviva
Innoviva is a diversified holding company with a portfolio of royalties and other healthcare assets, partnering with firms that advance innovative therapies to improve patient care.
Renaissance Holding Company
Renaissance Holdings is a prominent developer recognized for its commitment to high-quality infrastructure and long-term value creation across diverse market segments.
Delta Dental of New Jersey
Delta Dental of New Jersey is a leading dental benefits provider that also engages in strategic healthcare investments to support broader medical advancements.
What's next for Armata Pharmaceuticals?
With the recent infusion of capital, Armata Pharmaceuticals is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic focus will likely center on advancing its lead candidates through Phase 2 and Phase 3 clinical trials, while simultaneously optimizing its manufacturing processes for large-scale production. As the company navigates the complexities of regulatory approval, the continued support from institutional investors will be vital in maintaining its competitive edge. Future growth will depend on the successful demonstration of efficacy and safety in human trials, which could potentially redefine the standard of care for patients suffering from recalcitrant bacterial infections. The firm remains a key player to watch as it transitions from a research-heavy entity to a commercial-stage biotech leader.
See full Armata Pharmaceuticals company page
